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ulation, 16 but the impact of this polymorphism on clinical cardiac events among Japanese patients receiving clopidogrel remains unclear. The purpose of the present study was to assess the relationship between the CYP2C19*2 polymorphism and the frequency of cardiac events in Japanese patients receiving clopidogrel after DES implantation. Because DES thrombosis is a rare complication, 5 optical coherence tomography (OCT) was also used to evaluate the incidence of subclinical intra-stent thrombus.
Methods

Patients
The present study was approved by the ethics committee of Kobe University, and all enrolled patients provided their written informed consent to participate in the clinical trial and genetic study.
Between January 2008 and January 2010, 367 patients at Kobe University Hospital underwent percutaneous coronary intervention (PCI) with a DES (sirolimus-eluting stent (SES), Cypher™; Cordis, Miami Lakes, FL, USA; paclitaxel-eluting stent (PES), TAXUS Express™ or TAXUS Liberte™; Boston Scientific, Natick, MA, USA). All PCIs were performed under intravascular ultrasound guidance (Boston Scientific or Volcano, Rancho Cordova, CA, USA). If the patients revisited hospital for any reason (symptomatic or not), they were encouraged to undergo follow-up angiography and OCT provided that there were no contraindications. Of the 367 patients, 274 patients underwent follow-up angiography. To ensure patient safety during OCT, patients with left main trunk disease, ostial disease, and severe triple vessel disease (n=36) were excluded from the study. Patients with severe tortuous lesions and severely calcified vessels (n=33) were also excluded from the study due to anticipated difficulties advancing the OCT catheters. In addition, patients with vessels >4.0 mm in diameter on angiography (n=18) were excluded, because these vessels might be too large for blood flow to be occluded. Furthermore, patients who did not take clopidogrel chronically at the time of the follow-up angiography (n=12) and patients who did not agree to genetic analysis (n=42) were excluded. Of the remaining 133 patients, 108 agreed to undergo OCT during the follow-up angiography.
We assessed patient characteristics, including age, sex, body mass index and the presence of coronary risk factors (hypertension, dyslipidemia, diabetes mellitus, and smoking). Additional drug treatments were also assessed, because the response to clopidogrel might be reduced by concomitant medication, such as proton-pump inhibitors and statins. A previous report demonstrated that the proton-pump inhibitor omeprazole significantly decreases the inhibitory effect of clopidogrel on platelet P2Y12, 17 therefore we specifically assessed the use of omeprazole between the 2 groups.
All patients with a DES implantation received dual antiplatelet therapy consisting of aspirin and clopidogrel. The loading dose of clopidogrel (300 mg) was administered at least 24 h before the procedure, followed by a maintenance dose of clopidogrel (75 mg/day) and aspirin (100 mg/day) until follow-up.
Major adverse cardiac events (MACE) were defined as death, myocardial infarction, and target vessel revascularization. Target vessel revascularization was defined as any intervention required (surgical or percutaneous) to treat luminal stenosis (>75% on angiography) occurring in the same coronary vessel treated at the index procedure, within and beyond the target lesion limits.
Blood Sampling and Genotyping
Blood samples were obtained from the arterial sheath at the time of follow-up angiography. Genomic DNA was extracted from whole blood using the commercially available QIAamp DNA™ Blood Mini kit (Qiagen, Venlo, the Netherlands) according to the manufacturer's instructions. CYP2C19*2 polymorphisms were genotyped using TaqMan™ Drug Metabolism Genotyping Assays (Applied Biosystems, Foster City, CA, USA) with the Applied Biosystems 7500 Real-Time PCR System. Briefly, the forward primer (5'-GATATGCAATAA-TTTTCCCACTATCATTG-3') and reverse primer (5'-GG-TGTTCTTTTACTTTCTCCAAAATATCAC-3') were used to amplify a sequence of CYP2C19 containing the single nucleotide polymorphism 681G>A (rs4244285) in exon 5. Two oligonucleotide probes were synthesized for each single nucleotide polymorphism. The oligonucleotide corresponding to the wild type was labeled with the fluorescent dye 6-carboxyfluorescein (5'-FAM-TTATTTCCCGGGAACC-3') and the oligonucleotide corresponding to the mutation was labeled with VIC™ at the 5' end (5'-VIC-ATTATTTCCCAGGAA-CC-3'). The 3' end of the probe carried a dark quencher that suppressed the fluorescence of the reporter dyes. During polymerase chain reaction, fluorescence developed when the oligonucleotide hybridized to perfectly matching DNA and the exonuclease activity of Taq polymerase separated the quencher from the reporter dye. After polymerase chain reaction, the fluorescence yield for the 2 dyes was measured and presented as a scatter plot.
Angiography
Cineangiograms were analyzed using a computer-assisted, automated edge detection algorithm (CMS-Medis Medical Imaging Systems, Leiden, the Netherlands). The outer diameter of the contrast-filled catheter was used for calibration and the minimal lumen diameter was obtained in the worst-view projection. Acute gain was defined as the difference between the minimal luminal diameter before and after PCI. Late loss was defined as the difference between the minimal luminal diameter immediately after the procedure and at the followup date. The lesion type was also assessed according to the American Heart Association/American College of Cardiology classification. 18 OCT OCT was carried out as previously reported. 19 Briefly, an over-the-wire occlusion balloon catheter (Helios™; LightLab Imaging, Westford, MA, USA) and an OCT imaging probe (ImageWire™; LightLab Imaging) were inserted into the distal end of the DES-implanted lesion. The entire length of the DES was imaged with an automatic pullback device at 1 mm/s and OCT data were recorded on a CD-ROM for offline analysis. Cross-sectional images were analyzed at 1-mm (15 frames) intervals. Bifurcation lesions with major side branches were excluded from the analysis.
Neointimal thickness inside each stent strut was measured at each cross-section. Stent diameters (maximum and minimum) and area were also measured manually. A stent strut with a measured thickness of 0 μm was defined as an uncovered strut, and a maximum distance of >170 μm between the center reflection of the strut and adjacent vessel surface was defined as stent malapposition. This criterion was determined by adding the actual strut thickness and polymer thickness to the OCT resolution limit (140 μm +10 μm + 20 μm in SES; 130 μm +14 μm + 20 μm in PES). 20, 21 The numbers of uncovered struts and malapposed struts were calculated and CYP2C19*2 Polymorphism and Intra-Stent Thrombus described as the frequency (number of uncovered or malapposed struts divided by the total number of struts in each patient). A stent eccentricity index and a neointimal unevenness score were calculated, because these parameters are reported to be predictive factors for intra-SES thrombus. 22 The stent eccentricity index was calculated as the minimum stent diameter divided by maximum stent diameter in each cross-section. The neointimal unevenness score was calculated as the maximum neointimal thickness in one cross-section divided by the mean neointimal thickness of the same cross-section. Intra-stent thrombus was defined as a mass protruding beyond the stent strut into the lumen with significant attenuation behind the mass. 23 A representative case of an intra-stent thrombus is shown in Figure. All images were analyzed by 2 independent observers blinded to the clinical presentation and lesion characteristics.
Statistical Analysis
All statistical analyses were performed using Medcalc Software (version 9.3; Mariakerke, Belgium). Continuous variables are presented as mean ± SD. Differences in continuous parameters between the 2 groups were calculated using a 2-tailed unpaired t-test. Categorical variables are presented as frequency counts. Comparison of categorical variables between the 2 groups was performed using the chi-square test. Values were considered statistically significant at P<0.05. Multivariate logistic regression analysis was used to determine the significant factors indicating the presence of an intrastent thrombus. Factors with univariate P<0.2 were entered into the multivariate analysis. Age and sex were entered into the multivariate model as exceptions.
Results
Of the 108 patients who underwent follow-up OCT, 8 were excluded due to poor image acquisition. Therefore, the data for 100 patients (SES 117, PES 61) were analyzed in the present study. Mean follow-up duration was 243.8±88.1 days (median, 223.5 days; range, 7-546 days).
Baseline characteristics of the study population are listed in Table 1 . Of the 100 patients, 42 had at least one *2 allele (*2 carriers) and the remaining 58 were CYP2C19 wild-type homozygotes (non-carriers). No significant differences in patient characteristics were noted between the 2 groups. There were no differences in the use of proton-pump inhibitors, including omeprazole, and statins between the 2 groups. Angiography and procedural characteristics are given in Table 2 . No differences in the quantitative coronary angiography data or procedural characteristics were noted between the 2 groups.
The incidence of MACE did not differ significantly between the 2 groups during the follow-up period ( Table 2) . The incidence of target lesion revascularization tended to be higher in *2 carriers than in non-carriers (*2 carriers, 26.1% vs. non-carriers, 10.3%, P=0.06). Further, while myocardial infarction occurred in 2 non-carriers due to a remote occlusive lesion, a definite stent thrombosis occurred in only one *2 carrier, resulting in in-hospital mortality.
We analyzed 2,747 cross-sectional OCT images and identified 19,267 struts. The OCT measurements and findings are listed in Table 3 . OCT measurements (minimum stent area, frequency of uncovered stent struts and stent malapposition, stent eccentricity index, and neointimal unevenness score) were equivalent between the 2 groups. Intra-stent thrombi were identified more frequently in *2 carriers than in non- Data are presented as mean ± SD or n (%).
Figure.
Representative case of intra-stent thrombus (white arrow). Intra-stent thrombus was defined as a mass protruding beyond the stent strut into the lumen with significant attenuation behind the mass.
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carriers (*2 carriers, 52.4% vs. non-carriers, 15.5%, P=0.0002) on OCT.
Results of univariate and multivariate logistic regression analyses for the presence of intra-stent thrombus are given in Table 4 . The CYP2C19*2 polymorphism was the only independent predictive factor for intra-stent thrombus.
Discussion
In the present study 42.0% of the study population had at least one *2 allele. Although there was no significant increase in MACE among Japanese *2 carriers receiving clopidogrel, subclinical intra-stent thrombi were identified more frequently in *2 carriers than in non-carriers. Multivariate logistic regression analysis showed that the presence of the CYP2C19*2 polymorphism was the only independent predictive factor for intra-stent thrombus.
Clopidogrel is a prodrug that must be metabolized in the liver to exert its anti-aggregation properties. The CYP2C19 isoenzyme is one determinant of the pharmacodynamic response to clopidogrel. Several studies have demonstrated an association between the CYP2C19 genotype and a diminished platelet response to clopidogrel and more cardiovascular events after stent implantation. 11,12,14, 15 Trenk et al reported an association between the CYP2C19*2 polymorphism and high on-treatment platelet reactivity after the administration of clopidogrel. 24 The presence of the CYP2C19*2 polymorphism is significantly associated with an increased risk of stent thrombosis following implantation of a coronary stent. 14 In the present study we demonstrated a significantly higher incidence of intra-stent thrombus in *2 carriers (52.4%) than in non-carriers (15.5%). The present data also support the notion that the CYP2C19*2 polymorphism contributes to thrombotic events after DES implantation through a poor response to clopidogrel.
To our knowledge there are no studies on the histology of DES re-stenosis lesions. Nagai et al reported that SES restenosis lesions are sometimes histologically identified as fibrin thrombosis and appear as low-signal lesions on OCT images. 25 In the present study some neointima in cases of DES re-stenosis patients appeared as low-signal lesions on OCT (data not shown), and target lesion revascularization tended to occur more often in *2 carriers than in non-carriers (P=0.06). Therefore, some subclinical intra-stent thrombi might eventually result in DES re-stenosis and some re-stenosed DES neointima might be configured by thrombi. This possibility leads to the hypothesis that the CYP2C19*2 polymorphism is associated with DES re-stenosis as well as intra-stent thrombus through a poor response to clopidogrel. Further investigation is needed to clarify the impact of genetic factors on lesion outcome after DES implantation.
The CYP2C19*2 polymorphism frequency varies by population and race. Approximately 30% of Caucasian, 18% of Mexican -American and 33% of African -American people have at least one *2 allele. 8,11,14, 26 In contrast, >50% of the Asian population has at least one *2 allele. 17, 27 In the present study 42.0% of the patients had at least one *2 allele, similar to the findings of a previous report. 27 Despite the high frequency of the CYP2C19*2 polymorphism in the Japanese population, however, the incidence of DES thrombosis in this population is lower than that in Western countries. 3-5,8, 14 There are potential reasons for this discrepancy. First, unlike in Western countries, DES implantation is rarely performed in patients with acute coronary syndrome, which is an established risk factor for stent thrombosis. Second, because a high body mass index is associated with high platelet reactivity in Table 2 .
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patients receiving clopidogrel, 28 the loading dose (300 mg) and the maintenance dose of clopidogrel (75 mg/day) may be too high for Japanese patients compared with Western patients due to differences in body size. Third, most of the Japanese study population evaluated by Kimura et al had been receiving ticlopidine. 5 Although clopidogrel and ticlopidine have similar mechanisms of action, their pharmacokinetics and pharmacodynamics are different. Production of the active metabolite of clopidogrel is strongly dependent on CYP2C19 and 3A4, whereas the metabolic pathways of ticlopidine are not necessarily dependent on these isoforms. 11-15, 29 Therefore, the anti-thrombotic effect after DES implantation might be different between Japanese people taking clopidogrel and those receiving ticlopidine because of the high frequency of the CYP2C19*2 polymorphism. Additional large-scale controlled studies are needed to clarify this point. Proton-pump inhibitors, particularly omeprazole, decrease clopidogrel-induced inhibition of platelet aggregation 17 and increase the risk of adverse outcomes in East Asian people receiving clopidogrel after PCI. 30 In the present study the concomitant use of proton-pump inhibitors was not a risk factor for intra-stent thrombi. The present study was a small, non-randomized study, however, and thus the power was not sufficient to determine their association. Further controlled, randomized studies are required to fully clarify these points.
There were several limitations to the present study. Only patients who revisited hospital were enrolled in the study. Therefore, some selection bias was likely. The small sample size did not provide sufficient power to identify differences in the clinical outcome between *2 carriers and non-carriers. Further, because of the small sample size, it remains unclear whether the CYP2C19*2 polymorphism is a real risk factor for stent thrombosis. Although a previous report demonstrated that the CYP2C19*2 polymorphism affects responsiveness to clopidogrel, 15, 16 we did not assess platelet aggregation in this population. Therefore, it is unclear whether the CYP2C19*2 polymorphism inhibits the anti-platelet effect of clopidogrel in the present study population.
